AbbVie - Stock Price History | ABBV

Historical daily share price chart and data for AbbVie since 2023 adjusted for splits. The latest closing stock price for AbbVie as of June 02, 2023 is 136.87.
  • The all-time high AbbVie stock closing price was 166.98 on April 08, 2022.
  • The AbbVie 52-week high stock price is 168.11, which is 22.8% above the current share price.
  • The AbbVie 52-week low stock price is 131.10, which is 4.2% below the current share price.
  • The average AbbVie stock price for the last 52 weeks is 149.84.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
AbbVie Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2022 143.7413 127.8895 166.9756 125.9570 158.6109 24.04%
2021 104.8570 95.0100 128.3712 93.2806 127.8706 32.40%
2020 80.2781 76.5455 97.9483 55.8709 96.5783 27.61%
2019 65.1009 72.1729 77.1439 53.0629 75.6822 1.50%
2018 77.4809 76.6289 96.6261 62.9683 74.5670 -0.98%
2017 57.8604 46.8702 76.4732 45.5319 75.3052 60.13%
2016 44.9148 41.6225 50.1432 37.3887 47.0279 9.88%
2015 44.2590 46.0714 50.9795 34.8745 42.8001 -6.46%
2014 38.3261 35.1930 48.7424 31.9607 45.7568 27.97%
2013 29.1733 22.8735 36.7773 21.9552 35.7549 0.00%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $235.427B $58.054B
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $414.348B 62.90
Johnson & Johnson (JNJ) United States $401.608B 15.20
Novo Nordisk (NVO) Denmark $354.470B 41.57
Merck (MRK) United States $281.478B 16.46
Pfizer (PFE) United States $214.635B 6.14
Novartis AG (NVS) Switzerland $205.834B 15.27